EN
SINOVAC Launches New Influenza Vaccine Production Facility
Plant will expand worldwide flu vaccine capacity while setting leading standards for quality and sustainability
April 10, 2023, Beijing, China – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced the start of operations at its new, state-of-the-art influenza vaccine production facility in Beijing recently. The plant, which complies with Chinese Good Manufacturing Practice (GMP) guidelines and utilizes green production processes, enables automated production at scale that expands SINOVAC capacity to meet the growing global demand for high-quality influenza vaccines.
SINOVAC is committed to leveraging digital and intelligent technologies to optimize the vaccine production process and ensure the highest quality. By adopting digital systems and tools, such as the manufacturing execution system (MES), laboratory information management system (LIMS), document management system (DMS), and warehouse management system (WMS), SINOVAC is able to track and monitor each step of the production process, from material procurement to transportation and storage, ensuring complete traceability and transparency.
The new facility features 100% fully automated egg inspection before and after virus inoculation, ensuring each egg is fully viable and healthy. And multiple step purification process ensures the acquisition of high-purity vaccine antigen.
In addition to its advanced technology and strict quality control measures, the plant incorporates recycling practices that promote environmental sustainability. For example, waste embryos are rendered harmless through proper treatment and then reused as fertilizer. The site also features wastewater and exhaust treatment systems in the cultivation area that meet national environmental standards, thus ensuring 100% biological safety. These investments result in a highly efficient production process that minimizes ecological impact.
SINOVAC has the most comprehensive portfolio of influenza vaccines in China, including the H5N1 flu vaccine, Panflu®, and world's first H1N1 flu vaccine, Panfu.1®, as well as China's first preservative-free trivalent influenza vaccine, Anflu®, and quadrivalent influenza vaccine, TetrAnflu®. Outside of China, TetrAnflu® has been approved in Bangladesh and the Dominican Republic for market use.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com